Clincosm LogoSign in Get a demo

Topical CBD for Musculoskeletal Pain

Sponsor
Apothyx, Co. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05411913
Collaborator
(none)
100
Enrollment
4.8
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Various OTC and CBD containing topicals are evaluated in a double blind survey. Each sample has a QR code that is to be scanned before applying. The QR code links to a survey form with application instructions and collects participant information and feedback.

Condition or Disease Intervention/Treatment Phase
  • Drug: GoodFOR Pain
  • Drug: Icy Hot
  • Drug: Tiger Balm
  • Drug: Bengay
  • Drug: CBD Clinic Muscle and Joint Pain Relief Ointment
  • Drug: CBD FX CBD Muscle and Joint Cream: Cooling Formula
  • Drug: Essential Wholesale Muscle Gel
  • Drug: Extract Labs Muscle Cream
 Phase 3

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Intervention Model Description:
Individuals are provided with a sample of topical substance to apply to a localized region of pain.Individuals are provided with a sample of topical substance to apply to a localized region of pain.
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Everything is masked by QR code - participant and intervention
Primary Purpose:
Treatment
Official Title:
Immediate Effect of Topical CBD for Musculoskeletal Pain
Anticipated Study Start Date :
Jul 1, 2022
Anticipated Primary Completion Date :
Oct 31, 2022
Anticipated Study Completion Date :
Nov 25, 2022

Outcome Measures

Primary Outcome Measures

  1. Pain Before/After Application [5 min post intervention]

    McGill Pain Questionnaire

Secondary Outcome Measures

  1. Efficiency [5 min post intervention]

    Time and Duration of Pain Relief

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • has Pain
Exclusion Criteria:

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Apothyx, Co.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Daniel Charles McShan, PhD, Chief Scientist, Apothyx, Co.
ClinicalTrials.gov Identifier:
NCT05411913
Other Study ID Numbers:
  • Topical-CBD-PAIN-001
First Posted:
Jun 9, 2022
Last Update Posted:
Jun 9, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:
Musculoskeletal Pain

Study Results

No Results Posted as of Jun 9, 2022